• Media
  • Careers
  • Contacts
CBP - Pioneering and developing Bi-targeting XDC technologyCBPCBPCBP

Pioneering and developing Bi-targeting XDC technology

Contacts
  • Who We Are
    • About CBP
    • Our Culture
    • Leadership
    • Our History
  • Science & Innovation
    • Approach
    • Platforms
    • World of Bi-XDC
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Publications
  • For Patient
    • Patient Safety
    • Clinical Sites
    • Expanded Access Policy

Yearly Archives: 2024

Author By adminPosted on October 12, 2024October 12, 2024

The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008

October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
Read More
Author By adminPosted on June 26, 2024July 3, 2024

Coherent Biopharma’s CBP-1019 has received Orphan Drug Designation from the FDA for three indications

On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
Read More
Author By adminPosted on June 5, 2024July 3, 2024

ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention

The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...
Read More
Author By adminPosted on April 10, 2024July 3, 2024

【AACR 2024】Coherent Biopharma Announced Latest Pipeline CBP-8008 Preclinical Research Progress

Recently, Coherent Biopharma disclosed the latest preclinical research progress of CBP-8008, at the 2024 American Association...
Read More
Author By adminPosted on March 16, 2024July 2, 2024

CoherentBiopharma made its appearance at the 14th World ADC Conference in London

From March 12 to 15, 2024, the 14th World Antibody-Drug Conjugate Conference (World ADC) was held in London, UK. Dr. Guitao Wang,...
Read More

Categories

  • News 26

Recent Posts

  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019February 23, 2025
  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008October 12, 2024
  • Coherent Biopharma’s CBP-1019 has received Orphan Drug Designation from the FDA for three indicationsJune 26, 2024
  • ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attentionJune 5, 2024
  • 【AACR 2024】Coherent Biopharma Announced Latest Pipeline CBP-8008 Preclinical Research ProgressApril 10, 2024

Archives

  • 2025 (1)
  • 2024 (5)
  • 2023 (6)
  • 2022 (4)
  • 2021 (3)
  • 2020 (4)
  • 2019 (1)
  • 2018 (2)

Meet CBP

  • Leadership
  • Our History
  • Our Culture

Science&Innovation

  • Approach
  • Platforms
  • World of Bi-XDC

Pipeline

  • Pipeline
  • Clinical Trials
  • Publications

For Patient

  • Patient Safety
  • Clinical Sites
  • Expanded Access Policy
Copyright © 2025 CBP  All rights reserved.